Search research articles
Contact Us
Filters
Showing results (171-180 of 564) with videos related to
Page
of 57
Sort By:
Experimental Dermatology
|
February 1, 1994
Cytokine system as potential target for antipsoriatic therapy
L Kemény, G Michel, A Dobozy, et al.
Clinical and Experimental Dermatology
|
December 11, 2002
Type 1 segmental cutaneous leiomyomatosis
K Lang, J Reifenberger, T Ruzicka, et al.
Journal of the American Academy of Dermatology
|
July 21, 2001
Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent
M Megahed, S Schmiedeberg, J Becker, et al.
Clinical and Experimental Dermatology
|
June 20, 2013
Treatment of Darier disease with oral alitretinoin
V Letulé, T Herzinger, T Ruzicka, et al.
Deutsche Medizinische Wochenschrift (1946)
|
March 1, 2012
[Friend or Foe?--Psoriasin and Koebnerisin: multifunctional defence molecules in skin differentiation, tumorigenesis and inflammation]
S Zwicker, D Bureik, T Ruzicka, et al.
Lancet (London, England)
|
January 6, 1996
High-dose UVA1 for urticaria pigmentosa
H Stege, E Schöpf, T Ruzicka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 7, 2010
Dead Sea climatotherapy for vitiligo: a retrospective study of 436 patients
T Czarnowicki, M Harari, T Ruzicka, et al.
Archives of Dermatological Research
|
January 1, 1991
12-Hydroxyeicosatetraenoic acid (12-HETE) is a chemotactic stimulus for epidermal cells
R Hein, E Gross, T Ruzicka, et al.
The British Journal of Dermatology
|
December 3, 1999
Effect of topical tazarotene in the treatment of congenital ichthyoses
B Hofmann, H Stege, T Ruzicka, et al.
Immunology Today
|
March 1, 1996
FK506 in the treatment of inflammatory skin disease: promises and perspectives
G Michel, L Kemeny, B Homey, et al.
Page
of 57
Search research articles
Search
Showing results (171-180 of 564) with videos related to
Sort By:
Page
of 57
Experimental Dermatology
|
February 1, 1994
Cytokine system as potential target for antipsoriatic therapy
L Kemény, G Michel, A Dobozy, et al.
Clinical and Experimental Dermatology
|
December 11, 2002
Type 1 segmental cutaneous leiomyomatosis
K Lang, J Reifenberger, T Ruzicka, et al.
Journal of the American Academy of Dermatology
|
July 21, 2001
Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent
M Megahed, S Schmiedeberg, J Becker, et al.
Clinical and Experimental Dermatology
|
June 20, 2013
Treatment of Darier disease with oral alitretinoin
V Letulé, T Herzinger, T Ruzicka, et al.
Deutsche Medizinische Wochenschrift (1946)
|
March 1, 2012
[Friend or Foe?--Psoriasin and Koebnerisin: multifunctional defence molecules in skin differentiation, tumorigenesis and inflammation]
S Zwicker, D Bureik, T Ruzicka, et al.
Lancet (London, England)
|
January 6, 1996
High-dose UVA1 for urticaria pigmentosa
H Stege, E Schöpf, T Ruzicka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 7, 2010
Dead Sea climatotherapy for vitiligo: a retrospective study of 436 patients
T Czarnowicki, M Harari, T Ruzicka, et al.
Archives of Dermatological Research
|
January 1, 1991
12-Hydroxyeicosatetraenoic acid (12-HETE) is a chemotactic stimulus for epidermal cells
R Hein, E Gross, T Ruzicka, et al.
The British Journal of Dermatology
|
December 3, 1999
Effect of topical tazarotene in the treatment of congenital ichthyoses
B Hofmann, H Stege, T Ruzicka, et al.
Immunology Today
|
March 1, 1996
FK506 in the treatment of inflammatory skin disease: promises and perspectives
G Michel, L Kemeny, B Homey, et al.
Page
of 57